Highlighting Novel and Emerging Monoclonal Antibody Therapy for Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
On-Demand 1.5 hour Accredited Webcast
This activity is supported by an educational grant from
Genentech, a member of the Roche Group.
Genentech, a member of the Roche Group.
Faculty Presenters
Arghavan Almony, MD
Vice President
Carolina Eye Associates, P.A.
Southern Pines, North Carolina
Adjunct Assistant Professor of Surgery
Campbell University School of Medicine
Buies Creek, North Carolina
Douglas S. Burgoyne, PharmD, FAMCP
Adjunct Associate Professor
University of Utah College of Pharmacy
Salt Lake City, Utah
Medical Writing Support
Jeannette Y. Wick, RPh, MBA, FASCP
Freelance Medical Writer
Arlington, Virginia
Assistant Director, Office of Pharmacy Professional Development
University of Connecticut School of Pharmacy
Storrs, Connecticut
Program Description
Diabetic macular edema (DME) and neovascular age-related macular degeneration (AMD) are leading causes of visual impairment and blindness, and as the prevalence of diabetes grows and the population ages, so will the number of individuals with these conditions. The consequences of visual impairment lead to challenges in performing activities of daily living and not only affect patients but also caregivers and providers. Vascular endothelial growth factor (VEGF) plays a critical role in the onset of DME and in the degeneration of photoreceptors in AMD, leading to central visual acuity loss. Intravitreal injections with anti-VEGF agents are effective and the standard of care for these conditions, but are associated with challenges such as injection burden that may hinder optimal outcomes, which necessitates further research into agents that may extend dosing intervals. This activity will present recent clinical data on approved agents, with a special focus on investigational anti-VEGF agents, delivery methods, and biosimilars in development. To provide cost-effective treatments to patients with DME and neovascular AMD, managed care professionals must apply real-world research and patient-reported outcomes to overcome gaps in current treatment modalities and promote patient adherence.
Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: May 24, 2021
Expiration date: May 24, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Classify the roles of angiopoietin-2 (Ang-2) and VEGF-A in the development of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
- Examine current treatments for nAMD and DME
- Investigate recent advances in dual targeted therapy for nAMD and DME including efficacy and safety data from clinical trials
- Identify opportunities for specialty pharmacists and managed care professionals to improve patient access to novel therapies
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-220-H01-P. The activity is available for CE credit through May 24, 2022.Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Arghavan Almony, MD, has the following financial relationships with commercial interests to disclose:
- Consultant: Allergan, Cardinal Health
Douglas S. Burgoyne, PharmD, FAMCP, has no financial relationships with commercial interests to disclose.
Medical Writer: Jeannette Y. Wick, RPh, MBA, FASCP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
